← Leaderboards
Peter L Greenberg
Stanford University
$164,917
Attributed
$164,917
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $9.4K · FY2005–08$10K$7.5K$5K$2.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$164,917 · 4
By mechanism
M01$164,917 · 4
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Keith O Hodgson$40,099,114
- Michele Barry$16,099,763
- Edward I Solomon$24,141,500
- John R Huguenard$33,937,491
- Peter Sarnow$27,278,753
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchCombination ChemotherapyNeoplasm /Cancer ChemotherapyAntineoplasticsCyclosporinesCytosine ArabinosideAcute Myelogenous LeukemiaPharmacokineticsMitoxantroneEtoposideNeoplasm /Cancer Relapse /RecurrenceClinical Trial Phase IPatient Oriented ResearchDrug Screening /EvaluationClinical Trial Phase IiBiotechnologyClinically SignificantAzacitidineAll SitesDesignDiagnosisDecitabine
Grant awards (7)
CLINICAL TRIAL: SUBJECTS WITH (MDS) RECEIVING HYPOMETHYLATIN AGENTS$9,443
M01 · FY2008 · RR · contact PI
MONOCLONAL ANTIBODY THERAPY FOR MYELODYSPLASTIC SYNDROME$8,352
M01 · FY2005 · RR
A Phase I Study of ZARNESTRA and GLEEVEC in Patients$7,408
M01 · FY2004 · RR
Safety and Efficacy Trial of Bevacizuman: Anti-VEGF mAb$5,038
M01 · FY2004 · RR
MITOXANTRONE, ETOPOSIDE, CYTARABINE, PSC 833 IN AML$134,676
M01 · FY2001 · RR
MITOXANTRONE, ETOPOSIDE, CYTARABINE, PSC 833 IN AML$0
M01 · FY2001 · RR
MITOXANTRONE, ETOPOSIDE, CYTARABINE, PSC 833 IN AML$0
M01 · FY2000 · RR